Trends in inpatient antiparkinson drug use in the USA, 2001-2012

European Journal of Clinical Pharmacology

Volumn 71, Issue 8, 2015, Pages 1011-1019

  Crispo, James A G ^a,b   Fortin, Yannick ^a   Thibault, Dylan P ^c   Emons, Matthew ^d   Bjerre, Lise M ^a,e,f   Kohen, Dafna E ^a   Perez Lloret, Santiago ^g   Mattison, Donald ^a,h   Willis, Allison W ^c   Krewski, Daniel ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Cerner Corporation   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

^f BRUYÈRE RESEARCH INSTITUTE   (Canada)

^g PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^h RISK SCIENCES INTERNATIONAL   (Canada)

Author keywords

Cohort study; Drug utilization; Medical records; Parkinson's disease; Pharmacoepidemiology

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; COGNITIVE DEFECT; DEMOGRAPHY; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; FALLING; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PARKINSON DISEASE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; UNITED STATES; VERY ELDERLY; CLINICAL PRACTICE; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CHOLINERGIC ANTAGONISTS; DOPAMINE AGONISTS; DRUG UTILIZATION; FEMALE; HUMANS; INPATIENTS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 84937525296     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1881-4     Document Type: Article

References (46)

1. Callesen MB, Scheel-Kruger J, Kringelbach ML, Moller A (2013) A systematic review of impulse control disorders in Parkinson's disease. J Park Dis 3:105-138
2. Weintraub D, Nirenberg MJ (2013) Impulse control and related disorders in Parkinson's disease. Neurodegener Dis 11:63-71
3. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6:826-829
4. Hsieh PH, Hsiao FY (2013) Risk of heart failure associated with dopamine agonists: a nested case-control study. Drugs Aging 30:739-745
5. Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, Mazzaglia G, Herings R, Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, Camp G, Zanettini R, Sturkenboom MC (2012) The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacol Res Off J Ital Pharmacol Soc 65:358-364
6. Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, Rascol O (2014) Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. Expert Opin Drug Saf 13:351-360
7. Renoux C, Dell'Aniello S, Brophy JM, Suissa S (2012) Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf 21:34-41
8. Steiger M, Jost W, Grandas F, Van Camp G (2009) Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 116:179-191
9. Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P (2008) Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci 35:173-178
10. Parkkinen L, O'Sullivan SS, Kuoppamaki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ (2011) Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 77:1420-1426
11. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ (2006) Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 66:976-982
12. de la Fuente-Fernandez R, Schulzer M, Mak E, Sossi V (2010) Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat Disord 16:365-369
13. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 26(Suppl 3):S2-S41
14. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American academy of neurology. Neurology 58:11-17
15. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26(Suppl 3):S42-S80
16. Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG (2003) Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60:529-533
17. Dahodwala N, Xie M, Noll E, Siderowf A, Mandell DS (2009) Treatment disparities in Parkinson's disease. Ann Neurol 66:142-145
18. Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, Brown C (2013) Antiparkinson drug use and adherence in medicare part d beneficiaries with Parkinson's disease. Clin Ther 35:1513-1525.e1. 2
19. Hollingworth SA, Rush A, Hall WD, Eadie MJ (2011) Utilization of anti-parkinson drugs in Australia: 1995-2009. Pharmacoepidemiol Drug Saf 20:450-456
20. Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Yamamoto M, Nakayama T (2014) Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PLoS One 9:e99021
21. Rosa MM, Ferreira JJ, Coelho M, Freire R, Sampaio C (2010) Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord 25:1053-1060
22. Trifiro G, Savica R, Morgante L, Vanacore N, Tari M, Moretti S, Galdo M, Spina E, Caputi AP, Arcoraci V (2008) Prescribing pattern of anti-Parkinson drugs in southern Italy: cross-sectional analysis in the years 2003-2005. Parkinsonism Relat Disord 14:420-425
23. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA (2010) Geographic and ethnic variation in Parkinson disease: a population-based study of us medicare beneficiaries. Neuroepidemiology 34:143-151
24. Pirtosek Z (2009) 'Bad guys' among the antiparkinsonian drugs. Psychiatr Danub 21:114-118
25. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015-1022
26. Spector W, Mutter R, Owens P, Limcangco R (2006) Transitions between nursing homes and hospitals in the elderly population, 2009: Statistical brief #141; Healthcare cost and utilization project (hcup) statistical briefs. Rockville MD
27. U.S. Food and Drug Administration: FDA announces voluntary withdrawal of pergolide products. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm (accessed March 24, 2015).
28. U.S. Food and Drug Administration: Prior approval supplement. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2008/020667s014,020667s017,020667s018ltr.pdf (accessed March 24, 2015)
29. Jankovic J (2000) Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 23:252-261
30. Jankovic J, Aguilar LG (2008) Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 4:743-757
31. Herrero MT, Pagonabarraga J, Linazasoro G (2011) Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies. Neurologist 17:S54-S66
32. Lynn S (2012) Caring for patients with Parkinson's disease. Am Nurse Today 7
33. Factor SA (2008) Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics J Am Soc Expe Neuro Ther 5:164-180
34. Halkias IA, Haq I, Huang Z, Fernandez HH (2007) When should levodopa therapy be initiated in patients with Parkinson's disease? Drugs Aging 24:261-273
35. Schapira AH (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord 23(Suppl 3):S515-S520
36. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA (2011) Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology 77:851-857
37. Willis AW, Schootman M, Tran R, Kung N, Evanoff BA, Perlmutter JS, Racette BA (2012) Neurologist-associated reduction in pd-related hospitalizations and health care expenditures. Neurology 79:1774-1780
38. Moore TJ, Glenmullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174:1930-1933
39. Brusa L, Bassi A, Stefani A, Pierantozzi M, Peppe A, Caramia MD, Boffa L, Ruggieri S, Stanzione P (2003) Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 110:373-380
40. Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P (2013) The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Funct Neurol 28:13-17
41. Weerkamp NJ, Tissingh G, Poels PJ, Zuidema SU, Munneke M, Koopmans RT, Bloem BR (2014) Parkinson disease in long term care facilities: a review of the literature. J Am Med Dir Assoc 15:90-94
42. VanItallie TB (2005) Subsyndromal depression in the elderly: underdiagnosed and undertreated. Metabolism 54:39-44
43. Willis AW, Schootman M, Kung N, Wang XY, Perlmutter JS, Racette BA (2014) Disparities in deep brain stimulation surgery among insured elders with Parkinson disease. Neurology 82:163-171
44. Leoni O, Martignoni E, Cosentino M, Michielotto D, Calandrella D, Zangaglia R, Riboldazzi G, Oria C, Lecchini S, Nappi G, Frigo G (2002) Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 11:149-157
45. Arasalingam A, Clarke CE (2014) Reasons for Parkinson's disease admissions in a large inner city hospital. Parkinsonism Relat Disord 20:237-238
46. Braga M, Pederzoli M, Antonini A, Beretta F, Crespi V (2014) Reasons for hospitalization in Parkinson's disease: a case-control study. Parkinsonism Relat Disord 20:488-492, discussion 488